SLC5A2 and diabetic kidney disease: In a mouse model of diabetic kidney disease, the SGLT2 inhibitor dapagliflozin was found to reduce the activation of YAP/TAZ pathway in human proximal tubular epithelial cells and to suppress expression of their target genes, connective tissue growth factor (CTGF) and amphiregulin, both involved in fibrosis [159].